A Study Assessing KB407 for the Treatment of Cystic Fibrosis
Phase 1
12
about 2.6 years
18+
5 sites in FL, IL, NC +1
About this study
Researchers are testing a treatment called KB407, given through nebulization, to see if it's safe and well-tolerated in adults with cystic fibrosis. The trial will last approximately 946 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive KB407 (Nebulization)
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: To evaluate safety and tolerability of KB407 based upon assessment of adverse events (frequency, severity, relatedness), and changes from baseline in physical examinations, vital signs, ECG, and clinical laboratory test results
Secondary: To evaluate the effects of KB407 on pulmonary function, as measured by change from baseline in absolute and percent predicted FEV1
Respiratory